BibTex RIS Cite

PROBİYOTİKLER - PREBİYOTİKLER ve BAĞIŞIKLIK SİSTEMİ

Year 2016, Volume: 10 Issue: 1, 22 - 25, 01.02.2016

Mustafa Karakan Mehmet Ali Elmacıoğlu Hüseyin Nazlıkul

Abstract

Probiyotik tanımlaması; belirli miktarlarda alındıklarında sağlığı olumlu yönde etkileyen mikroorganizmalar şeklindedir. Barsak lümenindeki yiyecek ve diğer materyallere karşı oluşturulan mukozal tabaka engeli mukoza hücreleri, mikroflora ve mukus ile birlikte oluşturulur. Bu mukozal tabaka lümende bulunan immünolojik veya patojenik potansiyeli olan faktörlere karşı en önemli savunma sistemidir. Bu mukozal savunma sisteminin oluşturulmasında mikroflora önemli bir role sahiptir. Gastrointestinal sistem ve/veya bağışıklık sisteminin disfonksiyonu ile seyreden birçok akut ve kronik hastalıkta probiyotiklerin güvenle kullanılmaları yararlı olacaktır. Bu hastalıklarda tedavinin başarısı flora düzenlenmesinin yanında nöralterapi uygulamaları ile belirgin biçimde artmaktadır

Keywords

Probiyotik prebiyotik barsak florası mikrobiota bağışıklık mukoza nöralterapi

References

  • Guarner F. Khan AG et al. World gastroenterologyorganisa ons global guidelines: Probio cs and prebio cs October 2011. J. Clin Gastroenterol 2012; 46:468-481
  • Nazlıkul H, Acarkan T. Barsak ve enterik sinir sisteminin regülasyondaki önemi. Bilimsel Tamamlayıcı Tıp, regülasyon ve Nöralterapi Dergisi-Bar- nat 2014:8;1, 1-7.
  • Guarner F. Perdigon G. Corthier G. Salminen S. Koletzko B. Morelli L. Sho- luld yoghurt cultures be considered probio c? Br J Nutr 2005;93:783- 786
  • Kaufman SH. Elie Metchnikoff ’s and Paul Ehrlich’s impact on infec on biology. Microbes İnfect 2008;10:1417-19
  • Ögel B. Türk Kültür Tarihine Giriş Cilt 4: Türklerde Yemek Kültürü. Ankara: Kültür Bakanlığı Yayınları No 638, 1985:19-24
  • Kara A. Coşkun T. Prebio kler probio kler, Yurdakök M. Yoğurdun Öykü- sü, Probio klerin tarihi. Akademi, İstanbul 2014: 1-35
  • Kelly G. Inulin-typeprebio cs: a review. Part 1. Altern Med Rev 2008:13:315-329
  • Kelly G. Inulin-typeprebio cs: a review. Part 2. Altern Med Rev 2009:14:36-55
  • Gibson GR, Roberfroid MB. Dietary modula on of the human colonic microbiota introducingthe consept of prebio cs. J Nutr 1995: 125:1401- 1412
  • Chen HL, Lu YH, Lin JJ, Ko LY. Eff ect of isomalto-oligosaccharides on bowel func ons and indicators of nutri onal status in cons pated elderly men. J Am Coll Nutr 2001; 20: 4-49
  • Probio cs and prebio cs. World Gastroenterology Organisa on Prac ce Guidline, May 2008
  • Beylo M. Eff ects of inulin-type fructans on lipid metabolism in man and animal models. Br J Nutr 205;93(suppl 1):S163-168
  • Fo adis Cl, Stoidis CN, Spyropoulos BG, Zografos ED. Role of probio- cs, prebio cs andsynbio cs in chemopreven on for colorectal cancer. World J Gastroenterol 2008; 14: 6453-7
  • Gourbeyre P, Denery S, Bodinier M. Probio cs, prebio cs and synbio cs: impact on the gut immune system and allergic reac ons. J Leukoc Biol 2011; 89: 685-95
  • Bongearts G, Severijnen R, Timmerman H. Eff ect of an bio cs, prebio- cs and probio cs in treatment for hepa c encephalopathy. Med Hypot- heses 2005; 64: 64-68
  • Probio cs and prebio cs h p://www. oharmstrong. ca/prebio cs_pro- bio cs. pdf
  • Saier MH Jr, Mansour NM. Probio cs and prebio cs in human health. J Mol Microbiol Biotechnol 2005; 10: 22-25
  • Cummings JH, Kong SC. Probio cs, prebio cs and an bio cs in infl am- matory bowel disease. Novar s Found Symp 2004; 263: 99-111
  • Sethi T. Probio cs in pediatric care. Explore(NY), review. 2009;5: 245-49
  • Sanz Y. Gut microbiota and probio cs in maternal and infant health. Am J Clin Nutr 2011; 94(suppl): 2000S-2005S.
  • Shanahan F. Probio cs in perspec ve. Gastroenterology 2010; 139: 1808-1812
  • Deshpande G, Rao S, Patole S. Progress in the fi eld of probio cs: year 2011. Curr Opin Gastroenterol 2011;27:13-18. Review.
  • Meadows-Oliver M, Reid V. Use of probio cs in pediatrics. J Pediatr He- alth care 2009; 23:194-197
  • Michail S. Probio cs: past, present and future perpec ves. Curr Pediatr Rev 2008;4:96-102
  • Erdoğan D. Enterik sinir sistemi(ESS) ve insan sağlığındaki rolü. Bilimsel Tamamlayıcı Tıp, regülasyon ve Nöralterapi Dergisi-Barnat 2015:9;3, 9-16
  • Nazlıkul H. Bozucu alan olarak barsaklar ve barsakların önemi: Nöraltera- pi, Nobel, İstanbul 2010;239-250.
  • Nazlıkul H. Detoksifi kasyonun tedavisini keşfet: Haya Keşfet An -aging Yaşam Klavuzu, 3. Baskı, Alfa, İstanbul 2013;371-394.
  • Erdoğan D. Kronik kabızlık. Bilimsel Tamamlayıcı Tıp, regülasyon ve Nöral- terapi Dergisi-Barnat 2008:3; 32-37.
  • Gren-Johnson J. Immunological responses to gut bacteria. J AOAC Intern 2012:95;35-49.
  • Lee YK, Mazmanian SK, Has microbiota played acri cal role inthe evolu- on of the adap ve immune system? Sience 2010;330:1768-1773.
  • Molloy MJ, Bouladoux N, Belkaid Y. İntes nal microbiota: shaping local and systemic immune responses. Sem Immunol 2012;24:58-86.
  • Acarkan T. Besin Hassasiye . Bilimsel Tamamlayıcı Tıp, regülasyon ve Nö- ralterapi Dergisi-Barnat 2012:15;18-23.
  • Round JL, Mazmanian SK. Inducible Foxp3+ regultory T-cell development by a commensal bacterum of the intes nal microbiota. Proc Natl Acad Sci USA 2010;107:12204-12209.
  • Romeo J, Nova E, Warnberg J, Gomez-Mar nez S, Diaz Ligia LE, Marcos A. Immunmodulatory eff ect of fi bres, probio cs and synbio cs in diff e- rent life-stage. Nutr Hosp. 2010;25:341-349.
  • Wullaert A. role of NF-kappaB ac va on in intes nal immune homeosta- sis. Int J Med Microbiol. 2010;300:49-56.
  • Konkel JE, Chen W. Balancing acts: the role of TGF-B in the mucosal im- mune system. Trends Mol Med. 2011;17:668-676.
  • Ayvaz DÇ, Tezcan İ. Probiyo k-prebiyo k ve mukozal immun sistem. Kara A, Çoşkun T(Editör) Prebiyo kler probiyo kler Akademi, İstanbul 2014;88-105
  • Boyle RJ, Robins-Browne RM, Tang ML. Probio c use in clinical prac ce: what are the risks? Am J Clin Nutr. 2006;83:1256-1264.

PROBIOTICS - PRAEBIOTICS AND IMMUN SYSTEM

Year 2016, Volume: 10 Issue: 1, 22 - 25, 01.02.2016

Mustafa Karakan Mehmet Ali Elmacıoğlu Hüseyin Nazlıkul

Abstract

The definiton of probiotics is micro-organisms that positively affect health when taken in certain amounts to the body. The mucosal layer barrier generated by mucosal cells, microflora and mucus which formed against food and other materials in intestinal lumen. This is the most important defense system towards factors of pathogenic potential or the immunological potential in the lumen. The microflora has an important role for the creation of mucosal defense system. Using probiotics safely will be helpful in many acute and chronic diseases followed by Gastrointestinal and/or immune system dysfunction. The regulation of intestinal flora increases with neuraltherapy applications

Keywords

probiotics prebiotics gut flora microbiota immunity mucosal neuraltherapy

References

  • Guarner F. Khan AG et al. World gastroenterologyorganisa ons global guidelines: Probio cs and prebio cs October 2011. J. Clin Gastroenterol 2012; 46:468-481
  • Nazlıkul H, Acarkan T. Barsak ve enterik sinir sisteminin regülasyondaki önemi. Bilimsel Tamamlayıcı Tıp, regülasyon ve Nöralterapi Dergisi-Bar- nat 2014:8;1, 1-7.
  • Guarner F. Perdigon G. Corthier G. Salminen S. Koletzko B. Morelli L. Sho- luld yoghurt cultures be considered probio c? Br J Nutr 2005;93:783- 786
  • Kaufman SH. Elie Metchnikoff ’s and Paul Ehrlich’s impact on infec on biology. Microbes İnfect 2008;10:1417-19
  • Ögel B. Türk Kültür Tarihine Giriş Cilt 4: Türklerde Yemek Kültürü. Ankara: Kültür Bakanlığı Yayınları No 638, 1985:19-24
  • Kara A. Coşkun T. Prebio kler probio kler, Yurdakök M. Yoğurdun Öykü- sü, Probio klerin tarihi. Akademi, İstanbul 2014: 1-35
  • Kelly G. Inulin-typeprebio cs: a review. Part 1. Altern Med Rev 2008:13:315-329
  • Kelly G. Inulin-typeprebio cs: a review. Part 2. Altern Med Rev 2009:14:36-55
  • Gibson GR, Roberfroid MB. Dietary modula on of the human colonic microbiota introducingthe consept of prebio cs. J Nutr 1995: 125:1401- 1412
  • Chen HL, Lu YH, Lin JJ, Ko LY. Eff ect of isomalto-oligosaccharides on bowel func ons and indicators of nutri onal status in cons pated elderly men. J Am Coll Nutr 2001; 20: 4-49
  • Probio cs and prebio cs. World Gastroenterology Organisa on Prac ce Guidline, May 2008
  • Beylo M. Eff ects of inulin-type fructans on lipid metabolism in man and animal models. Br J Nutr 205;93(suppl 1):S163-168
  • Fo adis Cl, Stoidis CN, Spyropoulos BG, Zografos ED. Role of probio- cs, prebio cs andsynbio cs in chemopreven on for colorectal cancer. World J Gastroenterol 2008; 14: 6453-7
  • Gourbeyre P, Denery S, Bodinier M. Probio cs, prebio cs and synbio cs: impact on the gut immune system and allergic reac ons. J Leukoc Biol 2011; 89: 685-95
  • Bongearts G, Severijnen R, Timmerman H. Eff ect of an bio cs, prebio- cs and probio cs in treatment for hepa c encephalopathy. Med Hypot- heses 2005; 64: 64-68
  • Probio cs and prebio cs h p://www. oharmstrong. ca/prebio cs_pro- bio cs. pdf
  • Saier MH Jr, Mansour NM. Probio cs and prebio cs in human health. J Mol Microbiol Biotechnol 2005; 10: 22-25
  • Cummings JH, Kong SC. Probio cs, prebio cs and an bio cs in infl am- matory bowel disease. Novar s Found Symp 2004; 263: 99-111
  • Sethi T. Probio cs in pediatric care. Explore(NY), review. 2009;5: 245-49
  • Sanz Y. Gut microbiota and probio cs in maternal and infant health. Am J Clin Nutr 2011; 94(suppl): 2000S-2005S.
  • Shanahan F. Probio cs in perspec ve. Gastroenterology 2010; 139: 1808-1812
  • Deshpande G, Rao S, Patole S. Progress in the fi eld of probio cs: year 2011. Curr Opin Gastroenterol 2011;27:13-18. Review.
  • Meadows-Oliver M, Reid V. Use of probio cs in pediatrics. J Pediatr He- alth care 2009; 23:194-197
  • Michail S. Probio cs: past, present and future perpec ves. Curr Pediatr Rev 2008;4:96-102
  • Erdoğan D. Enterik sinir sistemi(ESS) ve insan sağlığındaki rolü. Bilimsel Tamamlayıcı Tıp, regülasyon ve Nöralterapi Dergisi-Barnat 2015:9;3, 9-16
  • Nazlıkul H. Bozucu alan olarak barsaklar ve barsakların önemi: Nöraltera- pi, Nobel, İstanbul 2010;239-250.
  • Nazlıkul H. Detoksifi kasyonun tedavisini keşfet: Haya Keşfet An -aging Yaşam Klavuzu, 3. Baskı, Alfa, İstanbul 2013;371-394.
  • Erdoğan D. Kronik kabızlık. Bilimsel Tamamlayıcı Tıp, regülasyon ve Nöral- terapi Dergisi-Barnat 2008:3; 32-37.
  • Gren-Johnson J. Immunological responses to gut bacteria. J AOAC Intern 2012:95;35-49.
  • Lee YK, Mazmanian SK, Has microbiota played acri cal role inthe evolu- on of the adap ve immune system? Sience 2010;330:1768-1773.
  • Molloy MJ, Bouladoux N, Belkaid Y. İntes nal microbiota: shaping local and systemic immune responses. Sem Immunol 2012;24:58-86.
  • Acarkan T. Besin Hassasiye . Bilimsel Tamamlayıcı Tıp, regülasyon ve Nö- ralterapi Dergisi-Barnat 2012:15;18-23.
  • Round JL, Mazmanian SK. Inducible Foxp3+ regultory T-cell development by a commensal bacterum of the intes nal microbiota. Proc Natl Acad Sci USA 2010;107:12204-12209.
  • Romeo J, Nova E, Warnberg J, Gomez-Mar nez S, Diaz Ligia LE, Marcos A. Immunmodulatory eff ect of fi bres, probio cs and synbio cs in diff e- rent life-stage. Nutr Hosp. 2010;25:341-349.
  • Wullaert A. role of NF-kappaB ac va on in intes nal immune homeosta- sis. Int J Med Microbiol. 2010;300:49-56.
  • Konkel JE, Chen W. Balancing acts: the role of TGF-B in the mucosal im- mune system. Trends Mol Med. 2011;17:668-676.
  • Ayvaz DÇ, Tezcan İ. Probiyo k-prebiyo k ve mukozal immun sistem. Kara A, Çoşkun T(Editör) Prebiyo kler probiyo kler Akademi, İstanbul 2014;88-105
  • Boyle RJ, Robins-Browne RM, Tang ML. Probio c use in clinical prac ce: what are the risks? Am J Clin Nutr. 2006;83:1256-1264.
There are 38 citations in total.

Details

Other ID JA69MG93SV
Journal Section Research
Authors

Mustafa Karakan This is me

Mehmet Ali Elmacıoğlu This is me

Hüseyin Nazlıkul This is me

Publication Date February 1, 2016
Published in Issue Year 2016 Volume: 10 Issue: 1

Cite

APA Karakan, M., Elmacıoğlu, M. A., & Nazlıkul, H. (2016). PROBİYOTİKLER - PREBİYOTİKLER ve BAĞIŞIKLIK SİSTEMİ. Bilimsel Tamamlayıcı Tıp Regülasyon Ve Nöral Terapi Dergisi, 10(1), 22-25.
AMA Karakan M, Elmacıoğlu MA, Nazlıkul H. PROBİYOTİKLER - PREBİYOTİKLER ve BAĞIŞIKLIK SİSTEMİ. BARNAT. February 2016;10(1):22-25.
Chicago Karakan, Mustafa, Mehmet Ali Elmacıoğlu, and Nazlıkul Hüseyin. “PROBİYOTİKLER - PREBİYOTİKLER Ve BAĞIŞIKLIK SİSTEMİ”. Bilimsel Tamamlayıcı Tıp Regülasyon Ve Nöral Terapi Dergisi 10, no. 1 (February 2016): 22-25.
EndNote Karakan M, Elmacıoğlu MA, Nazlıkul H (February 1, 2016) PROBİYOTİKLER - PREBİYOTİKLER ve BAĞIŞIKLIK SİSTEMİ. Bilimsel Tamamlayıcı Tıp Regülasyon ve Nöral Terapi Dergisi 10 1 22–25.
IEEE M. Karakan, M. A. Elmacıoğlu, and H. Nazlıkul, “PROBİYOTİKLER - PREBİYOTİKLER ve BAĞIŞIKLIK SİSTEMİ”, BARNAT, vol. 10, no. 1, pp. 22–25, 2016.
ISNAD Karakan, Mustafa et al. “PROBİYOTİKLER - PREBİYOTİKLER Ve BAĞIŞIKLIK SİSTEMİ”. Bilimsel Tamamlayıcı Tıp Regülasyon ve Nöral Terapi Dergisi 10/1 (February 2016), 22-25.
JAMA Karakan M, Elmacıoğlu MA, Nazlıkul H. PROBİYOTİKLER - PREBİYOTİKLER ve BAĞIŞIKLIK SİSTEMİ. BARNAT. 2016;10:22–25.
MLA Karakan, Mustafa et al. “PROBİYOTİKLER - PREBİYOTİKLER Ve BAĞIŞIKLIK SİSTEMİ”. Bilimsel Tamamlayıcı Tıp Regülasyon Ve Nöral Terapi Dergisi, vol. 10, no. 1, 2016, pp. 22-25.
Vancouver Karakan M, Elmacıoğlu MA, Nazlıkul H. PROBİYOTİKLER - PREBİYOTİKLER ve BAĞIŞIKLIK SİSTEMİ. BARNAT. 2016;10(1):22-5.